

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 19/10, 19/20; C07F 9/09 C07F 9/40	A1	(11) International Publication Number: WO 90/08155 (43) International Publication Date: 26 July 1990 (26.07.90)
(21) International Application Number: PCT/US89/05766 (22) International Filing Date: 21 December 1989 (21.12.89) (30) Priority data: 300,264 23 January 1989 (23.01.89) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 210 W. Seventh Street, Austin, TX 78701 (US). (72) Inventor: FARQUHAR, David ; 5134 Rutherglenn, Houston, TX 77096 (US). (74) Agent: GOODMAN, Kenneth, D.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report</i> <i>With amended claims and statement</i>
(54) Title: BIOLOGICALLY REVERSIBLE PHOSPHATE AND PHOSPHONATE PROTECTIVE GROUPS		
(57) Abstract Protective groups are provided which are suitable for masking phosphates and phosphonates. The protected compositions can be introduced in a biological system and then demasked under certain biological conditions. This method permits phosphates and phosphonates which would themselves degrade in the biological system and therefore be ineffective to be introduced in a protected form and later released under the proper conditions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

5

1

10

BIOLOGICALLY REVERSIBLE PHOSPHATE
AND PHOSPHONATE PROTECTIVE GROUPS

15

20 This patent application is a continuation-in-part of
Serial No. 848,781, filed on April 4, 1986, which was a
continuation-in-part of Serial No. 445,653, filed on
November 30, 1982, now abandoned. Both of those
documents are incorporated here by reference.

25 This invention relates to the use of biologically
reversible protective groups in medicinal chemistry.
More particularly, it relates to providing ionic
phosphate and phosphonate compounds intracellularly in
biological systems through the use of biologically
reversible protective groups.

30

35 Bioreversible protective groups and their uses are
well-known in medicinal chemistry. Some compounds that
are potentially useful in biological systems cannot be
directly provided in those systems, because they will be
rapidly decomposed or are otherwise incompatible with
that biological environment in a way that renders them
ineffective. However, when this type of compound is
derivatized with protective groups, the composite product
usually has different physical and chemical properties
40 than the parent. These modified properties can make the
product suitable for introduction into certain biological
environments that its parent is not. If the protective
groups are later removed under biological conditions, the
parent compound is left to perform its useful function.

This general method has a number of applications. For example, if the parent is unstable under the relevant biological conditions, it can be derivatized with protective groups which will create a more stable product. The protective groups can be selected so that they will be removed under predetermined biological conditions that exist at the site in the system where the parent is needed.

One area where this concept has apparently not yet been applied with satisfactory results is in the manipulation of phosphate and phosphonate compounds. These compounds, particularly phosphomonoesters and phosphodiester, play a key role in cellular metabolism. They are involved in almost every metabolic sequence, including the synthesis of carbohydrates, lipids, amino acids, proteins, nucleotides and nucleic acids. One logical way to regulate these metabolic processes is to inhibit intracellular phosphate metabolizing enzymes by using structurally analogous phosphates. These phosphoesters have very substantial therapeutic potential, but thus far they have not been practically useful, because they usually cannot penetrate cell membranes.

There are two reasons for this penetration problem. First, these phosphoesters are negatively charged at physiologic pH and are highly hydrophilic. Consequently, they are chemically incompatible with lipid membranes. Second, most of these compounds are rapidly degraded by enzymes in the blood and on cell surfaces.

As an example, most purine and pyrimidine antimetabolites used in the treatment of cancer require intracellular conversion to the corresponding 5'-mono-, di-, or tri-phosphates in order to exert cytotoxicity.

In experimental tumors, resistance to these agents frequently correlates with the deletion or decreased activity of enzymes that convert the administered drugs to the 5'-mononucleotides.

5

These problems have been recognized since about 1955. A number of attempts have been made to overcome them by using protective groups to change the phosphates into neutral, lipophilic derivatives which could resist the blood and cell surface enzymes. These derivatives would theoretically enter the target cells and then be demasked. This has apparently never been satisfactorily achieved in practice. Prior art masked phosphates have basically proved to be biologically inert. This is believed to be attributable to their failure to demask under biological conditions.

15

Thus, there remains a need for means to provide useful phosphates and phosphonates intracellularly. For this goal to be achieved through the use of protective groups, the masked phosphate must not be degraded by blood or cell surface enzymes and the protective groups must be removed under the biological conditions that exist in the target cells.

20

25


Bioreversibly protected phosphate or phosphonate compositions in accordance with the present invention use either of two types of protective groups that can be cleared by enzymes known to exist in the body.

30

("Bioreversibly protected phosphate or phosphonate composition" is used in this specification and the appended claims to refer to a parent phosphate or phosphonate which has been derivatized with a protective group or groups.) When a phosphate is derivatized with the first type of protective group, the protected composition has the formula:

35


4



5

When a phosphonate is derivatized with the first type of protective group, the protected composition has the formula:

10



15

R^1 can be hydrogen; alkyl, alkaryl, or aryl hydrocarbon, or an organic derivative thereof (e.g., nitroalkyl, haloalkyl, aminoalkyl, carboxyalkyl, nitroaryl, haloaryl, aminoaryl, carboxyaryl, etc.); or amine. R^1 is preferably an alkyl, alkaryl, or aryl hydrocarbon having from 1-10 carbon atoms; or an amine having the formula NR^4R^5 , where R^4 and R^5 are independently hydrogen or an alkyl hydrocarbon having from 1-10 carbon atoms. R^1 is most preferably an alkyl, alkaryl, or aryl hydrocarbon having from 1-6 carbon atoms; or $N(CH_3)_2$.

25


R^2 , part of the parent phosphate or phosphonate, can be any organic or inorganic residue, such as a sugar, nucleoside, lipid, amino acid or polypeptide. R^2 is preferably hydrogen; an alkyl, alkaryl, aryl or alkoxy carbonyl hydrocarbon; or a nucleoside such as a 2'-deoxynucleoside.

30

When a phosphate or phosphonate is derivatized with the second type of protective group, the protected composition has the formula:

35

5



5

R^1 can be hydrogen, alkyl hydrocarbons having 1-10 carbons, alkaryl or aryl hydrocarbons having 6-10 carbons, or organic derivatives thereof, or amine. When R^1 is an amine it preferably has the formula NR^4R^5 , where R^4 and R^5 are independently hydrogen or an alkyl hydrocarbon having from 1-10 carbon atoms. R^1 is most preferably an alkyl, alkaryl, or aryl hydrocarbon having from 1-6 carbon atoms; or $\text{N}(\text{CH}_3)_2$. Specific preferred examples are H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$.

15

R^3 is hydrogen or an alkyl hydrocarbon having 1-3 carbons, preferably hydrogen or a methyl group.

20

X^1 is selected from the group consisting of H and R^1COOCR^3 , while X^2 is selected from the group consisting of R^2 and OR^2 .

25

R^2 , part of the parent phosphate or phosphonate, again can be any organic or inorganic residue, such as a sugar, nucleoside, lipid, amino acid or polypeptide. R^2 is preferably selected from the group consisting of hydrogen, alkyl hydrocarbons having 1-10 carbons, aryl and alkaryl hydrocarbons having 6-10 carbons, and nucleosides.

30

R^2 substituents that are particularly useful include uracil 2',3'-dideoxynucleosides, cytosine 2',3'-dideoxynucleosides, purine 2',3'-dideoxynucleosides, and pyrimidine acyclic nucleosides.

35

Both types of protected compositions are resistant to the blood and cell surface enzymes that degrade the

parent phosphates. Furthermore, they both demask under biological conditions, so that at least some of the parent phosphates or phosphonates will be able to perform their desired intracellular functions.

5

The demasking mechanism is believed to be slightly different for the two types of protected compositions. For the first type, it appears to begin with the degradation of the protected phosphate or phosphonate to an unstable intermediate by carboxylate esterase. Cell-penetration may occur before or after this step. However, once the parent compound is completely demasked, it is once again unable to penetrate cell membranes. The unstable intermediate spontaneously ring opens to form its aldehydo tautomer. Next, the tautomer spontaneously eliminates acrolein, leaving the parent phosphate or phosphonate.

10

15

20

25

30

The demasking mechanism for the second type also appears to begin with degradation by carboxylate esterase, this time forming an unstable first intermediate. The first intermediate spontaneously eliminates an aldehyde or ketone to create a second intermediate, which is in turn degraded by carboxylate esterase to form an unstable third intermediate. The third intermediate spontaneously eliminates another aldehyde or ketone, leaving the parent phosphate or phosphonate. As with the first type, cell-penetration can be before or after degradation begins, but must be before the phosphate or phosphonate is completely demasked.

35

With either type of protective group, some of the protected compositions may break down outside cell membranes. However, at least some of the phosphates or phosphonates should be released within the target cells where they can be used for a variety of purposes.

One species of the second type of protective group, acyloxymethyl radicals, has been used in the past to mask carboxylic acids. However, neither they nor the first type have apparently ever been used in conjunction with phosphates or phosphonates.

The R^1 and R^3 substituents on these two types of protective groups can be modified to give the masked composition almost any desired physical or chemical property. By thus controlling the properties of the protected composition, variables such as location and rate of demasking can be controlled. This method has potential applications in modulating biochemical pathways, abrogating metabolic deficiencies, circumventing resistance to anticancer drugs and developing new anticancer, antiviral, and antiparasitic drugs.

In accordance with the present invention:

Figure 1 shows the demasking mechanism believed to occur for the first type of phosphate protective group; and

Figure 2 shows the demasking mechanism believed to occur for the second type of phosphate protective group.

The present invention relates to protective groups that can be used to mask phosphates or phosphonates. The protected composition demasks under biological conditions, thus leaving the parent phosphate or phosphonate available for reaction. This method has potential medical applications with any phosphate or phosphonate which has a therapeutic effect. (As used in this application and the appended claims, "therapeutic effect" means the diagnosis, cure, mitigation, treatment,

or prevention of disease in man or other animals, or an effect on the structure or any function of the body of man or other animals.)

5 One type of protective group and a method for its use is shown in Figure 1. A parent phosphate 11 is derivatized with the first type of protective group to form a bioreversibly protected composition 12. The R^1 and R^2 substituents on this composition can be as
10 previously described.

 The protected composition 12 is introduced into a biological system. While the parent phosphate 11 could not penetrate cell membranes 10, the protected
15 composition 12 can. Carboxylate esterase degrades the protected composition 12, either before or after cell penetration, and produces an unstable intermediate 13. The intermediate 13 spontaneously ring opens to form its aldehydo tautomer 14. The tautomer 14 spontaneously
20 eliminates acrolein to give the parent ionic phosphate 11.

 The mechanism would be the same for a protected phosphonate.
25

 A second type of protective group and its use are shown in Figure 2. A parent phosphate 21 is derivatized with the second type of protective group to form a
30 protected composition 22. R^1 , R^2 , and R^3 can be as previously described. The protected composition 22 is capable of penetrating cell membranes 20, and can do so before or after degradation begins.

 Carboxylate esterase degrades the protected
35 composition 22 to an unstable first intermediate 23. The first intermediate 23 then spontaneously eliminates an aldehyde or ketone to create a second intermediate 24.

Carboxylate esterase degrades the second intermediate 24 to given an unstable third intermediate 25. This substance spontaneously loses an aldehyde or ketone, leaving the parent phosphate 21.

5

The mechanism would be the same for a protected phosphonate.

Several tests have been performed with both types of protected compositions. These protected compositions have proved to be biologically active, unlike the prior art masked phosphates. The stabilities of these protected compositions were determined in aqueous buffered solutions having pH ranging from 1 to 10, and also under selected biological conditions. Except for the acetoxymethyl derivatives of the second type, these phosphoesters were relatively stable in a neutral environment. They reverted to their parent compounds in acidic or basic media.

20

The derivatization reaction for both types of protected compositions can be carried out in a number of ways. Several possibilities are described below. Example 1 concerns the first type of protected composition and the remainder of the examples concern the second type.

25

Example 1

30

A solution of acrolein (6.72g, 8.01 ml) in anhydrous chloroform (50 ml) was cooled to 5°C in an ice bath. Dry hydrogen bromide gas was then introduced with stirring until the solution was saturated. Pivaloyl bromide (28.6g) was added, followed by 0.2g of zinc chloride, and the reaction mixture was stirred at room temperature for 5 days. The crude reaction product was directly fractionated to yield 16.4g of 1,3-dibromo-1-

35

pivaloyloxypropane. The boiling point of this product was 85°C at 1.5 mm Hg.

5 Anhydrous sodium iodide (1.24g, 0.0082 mole) was dissolved in dry acetone (25 ml), and the solution was treated dropwise with stirring under a dry nitrogen atmosphere with a solution of the 1,3-dibromo-1-pivaloyloxypropane (1.00g, 0.0033 mole) in acetone (3.0 ml). After stirring at ambient temperature for 3 hours, 10 the reaction mixture was poured into dry hexane (150 ml).

Insoluble salts were removed by filtration, under nitrogen, through a bed of diatomaceous earth. The yellow filtrate was concentrated on a rotary evaporator 15 at less than 30°C. The remaining oil was taken up in dry hexane (30 ml) and again filtered to remove some insoluble residue. The solution was concentrated as described above to give 1.40g of a light yellow oil.

20 On attempted distillation this product underwent extensive decomposition. Since the IR, NMR and MS of the compound were consistent with the anticipated structure, and since the compound gave satisfactory elemental analytical data, it was used in subsequent reactions 25 without further purification.

Next a solution of the 1,3 diiodo-1-pivaloyloxypropane (1.4g) in dry ethylene glycol dimethyl ether (10 ml) was added with stirring under a dry 30 nitrogen atmosphere to a solution of bis(tetrabutylammonium)phenyl phosphate (2.17g, 0.0033 mole) in dry ethylene glycol dimethyl ether (200 ml). (Thus, R² was C₆H₅.) The reaction mixture was refluxed for 2 hours and then cooled to room temperature and 35 filtered through a sintered glass funnel.

After removal of solvent on a rotary evaporator at


less than 80°C, the residual oil was preadsorbed on dry-column silica gel (20g) which was then transferred to a 30" x 1" column of the same adsorbent. The column was developed with ethyl acetate-hexane (80/20, v/v).

5 Product bands were located by inspection under UV light (254 nm). The products were eluted from the silica gel with chloroform and further purified by chromatography on two thick-layer silica plates (20 cm x 20 cm x 2 mm).
10 The products, which were obtained as viscous oils, were shown by MS and NMR to be stereoisomers (arising from the presence of two chiral centers in the molecule at positions 2 and 4). The total yield for the four isomers was 210 mg.

15 Although the product was stable in organic solvents or aqueous buffers, it was quantitatively converted to phenyl phosphate when treated with strong acids or bases. Similarly, the product reverted to phenyl phosphate when
20 incubated at 37°C for 30 minutes with mouse plasma.

12

This synthesis can be summarized as follows:




This procedure was later repeated using bis(tetrabutylammonium) benzyl phosphate, i.e., with the R^2 substituent being $C_6H_5CH_2$.

Example 2

A disilver phosphate was obtained from the corresponding disodium salt by reaction with silver

nitrate in water. The disilver phosphate was reacted with a 2.5 molar excess of an iodomethyl ester in anhydrous benzene at room temperature for about 5 hours. The product was a bis(acyloxymethyl) phosphate. Several runs of this reaction were performed.

This synthesis can be summarized as follows:




In this run, the R^2 substituent of the parent phosphate was C_6H_5 and the R^1 substituent of the protective group was CH_3 . The product of this reaction was bis(acetoxymethyl) phenyl phosphate and the yield was 5%.

The protected product was stable in neutral aprotic solvents such as benzene, diethyl ether and ethyl acetate. However, in protonic solvents such as ethanol, water or 0.05 M potassium phosphate buffer (pH 7.4), it was slowly converted to mono(acetoxymethyl) phenyl phosphate. The half-life was greater than 4 hours.

These solutions were analyzed by (HPLC) high performance liquid chromatography (Waters model ALC 204). The disappearance of the bis(acyloxymethyl) phosphate was monitored by reversed-phase chromatography on a column of μ Bondapak- C_{18} (30 cm x 4 mm i.d., 10 μ m; Waters Assoc., Milford, Mass.) using solutions of 0.01 M potassium

phosphate buffer (pH 7.0) with methanol as the mobile phase (typically 25-50% alcohol).

The mechanism for this change is probably as shown below.



The bis(acetoxymethyl) phosphate A is solvolyzed to form an intermediate B, which spontaneously eliminates formaldehyde. A mono(acetoxymethyl) phosphate C results, and is further demasked to a next intermediate D and the parent phosphate E by repetition of the same steps. A labile intermediate was detected in some solutions by HPLC, but was not characterized.

The formation of intermediate B and mono(acetoxymethyl) phosphate C was monitored by ion-pair chromatography on μ Bondapak-C using the same buffer

system as described above, except that tetrabutylammonium hydroxide was added to a concentration 2×10^{-3} M, or by anion-exchange chromatography on a column of Partisil SAX (25 cm x 4.6 mm i.d., 10 μ m; Whatman) using a linear
5 gradient of 0.01-0.1 M potassium phosphate buffer (pH 6.5) as an eluent. The flow rates for these analyses and the ones described above ranged from 1.0 to 2.0 ml/min. The column effluents were monitored at 254 nm with a Schoeffel model 450 UV detector, and the concentrations
10 were determined by comparison of the peak areas with those of reference standards.

When the bis(acetoxymethyl) phenyl phosphate was incubated at a concentration of 65 micrograms per
15 milliliter at 37°C in 0.05 M potassium phosphate buffer (pH 7.4) with either hog liver carboxylate esterase (obtained from Sigma Chemicals, St. Louis, Mo.) (E.C. No. 3.1.1.1., 8 milligrams protein per milliliter) or mouse plasma (50% by volume) it was rapidly degraded, first to
20 the mono(acetoxymethyl) analog, and then to the parent phenyl phosphate. The half-life was less than 15 minutes. (At appropriate intervals, aliquots (100 μ l) of the incubation mixtures were diluted with 3 volumes of methanol and then agitated for 1 minute on a Vortex
25 shaker. The precipitated protein was separated by centrifugation at 10,000xg for 5 minutes, and the supernatants were analyzed by HPLC as described above.)

Example 3

30

In this case iodomethyl pivaloate was used (i.e., R¹ was C(CH₃)₃). Preparation was otherwise the same as in Example 2. The product, bis(pivaloyloxymethyl) phenyl phosphate, was produced with a 54% yield.

35

This phosphotriester was much more resistant to both chemical and enzymatic hydrolysis than the protected

composition of Example 1. It was stable in protonic solvents and had a half-life of about 5 hours when incubated with mouse plasma under the same conditions as in Example 2. This demonstrates that the acyl
5 substituent has a substantial effect on the rate of hydrolysis.

Example 4


10 Disilverbenzyl phosphate was reacted with iodomethyl pivaloate. The product was bis(pivaloyloxymethyl) benzyl phosphate. Catalytic hydrogenolysis of this product over 5% Pd-C in cyclohexane gave the corresponding monobasic acid. This acid was isolated in its cyclohexyl ammonium
15 salt form.

Successive ion exchange of the salt on Dowex 50 Na⁺ and Dowex 50 Ag⁺ produced silver bis(pivaloyloxymethyl) phosphate. This compound is very useful in synthesizing
20 other bis(acyloxymethyl) phosphoesters. For example, when reacted with benzyl bromide or methyl iodide in benzene at room temperature for about 5 hours, the corresponding benzyl and methyl phosphotriesters are produced in nearly quantitative yield.
25


The synthesis of this example can be summarized as follows:

30

17

Example 5

45 The silver diester product of Example 4 was reacted with 5'-deoxy-5'-iodo-3'-O-acetylthymidine, as shown below.



The R substituent shown was a methyl group.

35 The reaction was carried out under reflux for about 5 hours. Bis(pivaloyloxymethyl) 3'-O-acetylthymidine-5'-phosphate was produced in 39% yield.


Example 6

40 Example 5 was repeated with the R substituent changed to fluorine (i.e., 2',5-dideoxy-5'-iodo-3'-O-acetyl-5-fluorouridine). There was a 15% yield of this product. This composition prevented the growth of Chinese hamster ovary cells in culture at a concentration of 5.0×10^{-6} M [5-fluoro-2'-deoxyuridine (5-FUdR) control, 1.0×10^{-6} M].

45

Example 7

Several bis(acyloxymethyl) esters of 5-fluoro-2'-
5 deoxyuridine-5" phosphate (5-FdUMP) were prepared through
condensation of 5-FUdR or 3'-O-acetyl-5-FUdR with
bis(acyloxymethyl) phosphates. One in particular,



was incubated at 3°C with mouse plasma and hog liver
carboxylate esterase. The acyloxymethyl groups and the
3'-acetyl group were successively cleaved to give 5-
15 FdUMP. When the bis(acyloxymethyl) ester was tested, it
prevented the growth of Chinese hamster ovary cells in
culture at a concentration of 1×10^{-6} M. It also proved
active against P388 leukemia which is resistant to 5-
fluorouracil.

20

* * *

Other groups of compounds in accordance with the
present invention include the following:


- 25 A. Bis(acyloxymethyl) esters of uracil 2',3'-
dideoxynucleotides and substituted analogues.
B. Mono(acyloxymethyl) esters of uracil 2',3'-
dideoxynucleotides and substituted analogues.
C. Bis(acyloxymethyl) esters of cytosine 2',3'-
30 dideoxynucleotides and substituted analogues.
D. Mono(acyloxymethyl) esters of cytosine 2',3'-
dideoxynucleotides and substituted analogues.
E. Mono(acyloxymethyl) esters of purine 2',3'-
dideoxynucleotides and substituted analogues.
35 F. Mono(acyloxymethyl) and bis(acyloxymethyl) esters of
pyrimidine acyclic nucleotides.

Such compounds will be discussed in more detail in

Examples 8-14.

Example 8

5 Bis(acyloxymethyl) esters of uracil 2',3'-
dideoxynucleotides and substituted analogues.



15

		<u>I</u>	
		<u>R</u> ¹	<u>R</u> ²
	<u>I</u> 1	(CH ₃) ₃ C	2',3'-dideoxyuridine-5'-yl
20	<u>I</u> 2	(CH ₃) ₂ CH	2',3'-dideoxyuridine-5'-yl
	<u>I</u> 3	CH ₃ CH ₂	2',3'-dideoxyuridine-5'-yl
	<u>I</u> 4	CH ₃	2',3'-dideoxyuridine-5'-yl
25	<u>I</u> 5	(CH ₃) ₃ C	2'-fluoro-2',3'-dideoxyuridine-5'-yl
	<u>I</u> 6	(CH ₃) ₃ C	3'-fluoro-2',3'-dideoxyuridine-5'-yl
30	<u>I</u> 7	(CH ₃) ₃ C	3'-azido-2',3'-dideoxyuridine-5'-yl
	<u>I</u> 8	(CH ₃) ₃ C	3'-amino-2',3'-dideoxyuridine-5'-yl
	<u>I</u> 9	(CH ₃) ₃ C	5-chloro-2',3'-dideoxyuridine-5'-yl
35	<u>I</u> 10	(CH ₃) ₃ C	5-bromo-2',3'-dideoxyuridine-5'-yl
	<u>I</u> 11	(CH ₃) ₃ C	5-iodo-2',3'-dideoxyuridine-5'-yl

	5'-yl	
	<u>I</u> 12 (CH ₃) ₃ C	5-methyl-2',3'-dideoxyuridine-
	5'-yl	
5	<u>I</u> 13 (CH ₃) ₃ C	5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-
	yl	
	<u>I</u> 14 (CH ₃) ₃ C	5-methyl-3'-azido-2',3'-dideoxyuridine-5'-
	yl	
	<u>I</u> 15 (CH ₃) ₃ C	5-methyl-3'-amino-2',3'-dideoxyuridine-5'-
	yl	
10	<u>I</u> 16 (CH ₃) ₃ C	5-ethyl-2,3'-dideoxyuridine-5'-
	yl	
	<u>I</u> 17 (CH ₃) ₃ C	5-propyl-2',3'-dideoxyuridine-5'-
	yl	

15 The starting dideoxynucleotides were prepared as described in P. Herdewijn, J. Balzarini, E. DeClercq, R. Pauwels, B. Masanori, S. Broder, H. Vanderhaeghe, "3'-substituted 2',3'-Dideoxynucleoside Analogs as Potential Anti-HIV (HTLV-III/LAV) Agents," J. Med. Chem. 30, 1270-8 (1987); and references therein.

20 Except for the 3-amino analogues 8 and 16, all of the compounds were synthesized by condensing the parent nucleosides with the appropriate bis(acyloxymethyl) phosphate in dimethylformamide in the presence of

25 triphenylphosphine/diethyl azodicarboxylate as described above; a brief account of the procedure is given below. The 3-amino analogues 8 and 16 were prepared by catalytic reduction of the 3-azido analogues 7 and 15 over Pd/C by conventional

30 hydrogenation techniques. T. A. Krenitsky, G. A. Freeman, S. R. Shaver, et al, "3'-Amino-2',3'-dideoxyribonucleosides of Some Pyrimidines; Synthesis and Biological Activities," J. Med. Chem. 26, 891-895 (1983).

35

 The nucleoside analogue (1.0 mmol), triphenylphosphine (0.60 g, 2.28 mmol) and

bis(pivaloyloxymethyl) phosphate (0.5 g, 5.5 mmol) were dissolved in dimethylacetamide (10 mL) contained in a 15 mL round-bottom flask. A solution of diethyl azodicarboxylate (0.40 g, 2.29 mmol) in

5 dimethylacetamide (2 mL) was added dropwise over 30 minutes, and the mixture was allowed to stir for 3 days at ambient temperature. The solution was evaporated in vacuo then the residue was taken up in chloroform, filtered, and chromatographed on a column of silica

10 (Merck, 230-400 mesh; ca. 10 g) using ethyl acetate/hexane (typically 70:30) as eluent. Fractions of 5 mL were collected. Aliquots of each fraction were analyzed by ascending TLC on silica-coated glass plates (silica gel 60 F 254, Merck) using CHCl_3 -MeOH


15 (typically 1-10% MeOH) as the eluting solvent. Chromatograms were visualized under a UV lamp (254 nm). Compounds containing an acyloxymethyl group were identified by spraying the plates with a 0.25% solution of Purpald in 0.5 N NaOH solution and heating in an

20 oven at 85°C for 5 min. The formaldehyde liberated from the acyloxymethyl groups reacted with the spray reagent to form purple spots against a white background.

25 All of the products were obtained as viscous colorless oils.

Example 9

30 Mono(acyloxymethyl) esters of uracil 2',3'-dideoxynucleotides and substituted analogues.



	<u>Compound</u>	<u>R¹</u>	<u>R²</u>
	<u>II</u> 1 (CH ₃) ₃ C		2',3'-dideoxyuridine-5'-
	yl		
5	<u>II</u> 2 (CH ₃) ₂ CH		2',3'-dideoxyuridine-
	5'-yl		
	<u>II</u> 3 CH ₃ CH ₂		2',3'-dideoxyuridine-
	5'-yl		
	<u>II</u> 4 CH ₃		2',3'-dideoxyuridine-
	5'-yl		
10	<u>II</u> 5 (CH ₃) ₃ C		2'-fluoro-2',3'-dideoxyuridine-
	5'-yl		
	<u>II</u> 6 (CH ₃) ₃ C		3'-fluoro-2',3'-dideoxyuridine-
	5'-yl		
15	<u>II</u> 7 (CH ₃) ₃ C		3'-azido-2',3'-dideoxyuridine-
	5'-yl		
	<u>II</u> 8 (CH ₃) ₃ C		3'-amino-2,3'-dideoxyuridine-5'-
	yl		
	<u>II</u> 9 (CH ₃) ₃ C		5-chloro-2',3'-dideoxyuridine-5'-
	yl		
20	<u>II</u> 10 (CH ₃) ₃ C		5-bromo-2',3'-dideoxyuridine-
	5'-yl		
	<u>II</u> 11 (CH ₃) ₃ C		5-iodo-2',3'-dideoxyuridine-
	5'-yl		
	<u>II</u> 12 (CH ₃) ₃ C		5-methyl-2',3'-dideoxyuridine-
25	5'-yl		
	<u>II</u> 13 (CH ₃) ₃ C	5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-	
	yl		
	<u>II</u> 14 (CH ₃) ₃ C	5-methyl-3'-azido-2',3'-dideoxyuridine-5'-	
	yl		
30	<u>II</u> 15 (CH ₃) ₃ C	5-methyl-3'-amino-2',3'-dideoxyuridine-5'-	
	yl		
	<u>II</u> 16 (CH ₃) ₃ C	5-ethyl-2,3'-dideoxyuridine-5'-	
	yl		
	<u>II</u> 17 (CH ₃) ₃ C	5-propyl-2',3'-dideoxyuridine-5'-	
35	yl		


All of the compounds except for 8 and 16 were prepared from the parent nucleosides by condensation with mono(pivaloyloxymethyl) phosphate in pyridine in the presence of dicyclohexylcarbodiimide as described below. Compounds 8 and 16 were prepared by catalytic reduction of the 3-azido analogues 7 and 15 over Pd/C. T. A. Krenitsky, G. A. Freeman, S. R. Shaver, et al, "3'-Amino-2',3'-dideoxyribonucleosides of some Pyrimidines; Synthesis and Biological Activities," J. Med. Chem. 26, 891-895 (1983).

The nucleoside (1 mmol) was dried by repeated evaporation from pyridine (5 x 5 mL). It was then taken up in pyridine (5 mL) and the solution was cooled to 5°C. Monopivaloyloxymethyl phosphate (0.25 g, 1.2 mmol) was added followed by dicyclohexylcarbodiimide (0.25 g, 1.2 mmol). The reaction mixture was stirred at room temperature for 3 days then concentrated in vacuo at < 30°C to remove pyridine. Water (5.0 mL) was added then the solution was adjusted to pH 7.0 with acetic acid. The mixture was stirred for 10 minutes then the precipitated dicyclohexylurea was filtered off. The filtrate was passed through a column of Dowex 50 cation-exchange resin in the H⁺ form and the eluent was immediately frozen and lyophilized. The residual gum was purified by chromatography on a thick layer of silica (20 cm x 20 cm x 2 mm) using chloroform-methanol (typically 3:1) as eluent. The products were isolated as viscous colorless oils.

Example 10

Bis(acyloxymethyl) esters of cytosine 2',3'-dideoxynucleotides and substituted analogues.

25

III


10	<u>Compound</u>	<u>R¹</u>	<u>R²</u>
	<u>III</u> 1	(CH ₃) ₃ C	2',3'-dideoxycytidin-5'-yl
	<u>III</u> 2	(CH ₃) ₃ C	2'-fluoro-2',3'-dideoxycytidin-5'-yl
15	<u>III</u> 3	(CH ₃) ₃ C	3'-fluoro-2',3'-dideoxycytidin-5'-yl
	<u>III</u> 4	(CH ₃) ₃ C	3'-azido-2',3'-dideoxycytidin-5'-yl
	<u>III</u> 5	(CH ₃) ₃ C	5-fluoro-2',3'-dideoxycytidin-5'-yl
20	<u>III</u> 6	(CH ₃) ₃ C	5-chloro-2',3'-dideoxycytidin-5'-yl
	<u>III</u> 7	(CH ₃) ₃ C	5-bromo-2',3'-dideoxycytidin-5'-yl
25	<u>III</u> 8	(CH ₃) ₃ C	5-iodo-2,3'-dideoxycytidin-5'-yl
	<u>III</u> 9	(CH ₃) ₃ C	5-methyl-2',3'-dideoxycytidin-5'-yl
30	<u>III</u> 10	(CH ₃) ₃ C	5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl
	<u>III</u> 11	(CH ₃) ₃ C	5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl

These dideoxycytidine nucleotide esters were prepared by coupling the parent N-carbobenzyloxy nucleoside with bis(pivaloyloxymethyl) phosphate in the presence of triphenyl phosphine and diethyl azodicarboxylate as described for the uracil analogues,

I, above. The 4-amino groups were protected as their N-carbobenzyloxy derivatives as described for cytidine. K. Kondo, T. Nagara et al, "Studies on Biologically Active Nucleosides and Nucleotides, Part. 5," J. Med. Chem. 22, 639-646 (1979). When the coupling reaction was complete, the N-carbobenzyloxy protective groups were removed by hydrogenation over 5% palladium-on-charcoal in ethanol. The final products were isolated as the corresponding hydrochloride salts by treating a 10% solution of the free base in chloroform with an excess of a 5% solution of hydrogen chloride in ether. The precipitated hydrochlorides were filtered and dried under vacuum over P_2O_5 . For compound 7, the trichloroethoxycarbonyl protective group was used instead of the benzyloxycarbonyl group; it was removed with Zn/Cu in DMF as described in F. Eckstein, "The Trichloroethyl Group as a Protecting Group for Phosphate in the Synthesis of Mononucleotides," Angew. Chem. (Ger.) 77, 912 (1965).

Example 11

Mono(acyloxymethyl) esters of cytosine 2',3'-dideoxynucleotides and substituted analogues.



IV


<u>Compound</u>	<u>R¹</u>	<u>R²</u>
<u>IV</u> 1 yl	(CH ₃) ₃ C	2',3'-dideoxycytidin-5'-
<u>IV</u> 2 yl	(CH ₃) ₃ C	2'-fluoro-2',3'-dideoxycytidin-5'-
<u>IV</u> 3	(CH ₃) ₃ C	3'-fluoro-2',3'-dideoxycytidin-5'-

	yl		
	<u>IV</u> 4	(CH ₃) ₃ C	3'-azido-2',3'-dideoxycytidin-5'-yl
	yl		
	<u>IV</u> 5	(CH ₃) ₃ C	5-fluoro-2',3'-dideoxycytidin-5'-yl
5	yl		
	<u>IV</u> 6	(CH ₃) ₃ C	5-chloro-2',3'-dideoxycytidin-5'-yl
	yl		
	<u>IV</u> 7	(CH ₃) ₃ C	5-bromo-2',3'-dideoxycytidin-5'-yl
	yl		
10	<u>IV</u> 8	(CH ₃) ₃ C	5-iodo-2',3'-dideoxycytidin-5'-yl
	yl		
	<u>IV</u> 9	(CH ₃) ₃ C	5-methyl-2',3'-dideoxycytidin-5'-yl
	yl		
	<u>IV</u> 10	(CH ₃) ₃ C	5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl
15	<u>IV</u> 11	(CH ₃) ₃ C	5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl

These diesters were prepared from the parent N-benzyloxycarbonyl nucleosides by condensation with monopivaloyloxymethyl phosphate in pyridine as solvent in the presence of dicyclohexylcarbodiimide as described above for the uracil analogues II. In the final step the benzyloxycarbonyl protective groups were removed as usual by catalytic hydrogenation over 5% palladium-on-charcoal.

Example 12

Mono(acyloxymethyl) esters of purine 2',3'-dideoxynucleotides.



28


V

	<u>Compound</u>	<u>R¹</u>	<u>R²</u>
5	<u>V</u> 1	(CH ₃) ₃ C	2',3'-dideoxyadenosin-5'-yl
	yl		
	<u>V</u> 2	(CH ₃) ₃ C	2',3'-dideoxyguanosin-5'-yl
	yl		
10	<u>V</u> 3	(CH ₃) ₃ C	2',3'-dideoxyxanthosin-5'-yl

These compounds were prepared by reaction of the nucleoside analogue with mono(pivaloyloxymethyl) phosphate in pyridine as solvent in the presence of 2,4,6-triisopropylbenzenesulfonyl tetrazole as condensing agent by the general procedure described by D. E. Gibbs and L. E. Orgel, "Some 5'-Azido and 5'-amino-2'-deoxyribonucleosides, their 3'-phosphates, and their 3'-phosphoimidazolides," J. Carbohydrates, Nucleosides and Nucleotides, 3, 315-334 (1976).

Example 13

Mono(acyloxymethyl) and bis(acyloxymethyl) esters of pyrimidine acyclic nucleotides.

VI


These compounds were prepared from the parent free acyclic nucleotides (E. DeClercq and R. T. Walker, "Chemotherapeutic Agents for Herpesvirus Infections," Progress in Medicinal Chemistry, 23, 187-218 (1986); and references therein, and M. Mansuri and J. C. Martin, Annual Reviews in Medicinal Chemistry: Antiviral Agents,

22, 139-148 (1987); and references therein) by condensation with bis(acyloxymethyl) phosphate or mono(acyloxymethyl) phosphate by the general procedures described above for the uracil (I) and cytosine (III) analogues.

	<u>Compound</u>	R^1	<u>Base</u>
	<u>VI</u> 1	$(CH_3)_3C$	Thymine
10	<u>VI</u> 2	$(CH_3)_3C$	Uracil
	<u>VI</u> 3	$(CH_3)_3C$	Cytosine

Example 14

15 Mono(acyloxymethyl) esters of pyrimidine and purine acyclic nucleotides.



25

	<u>Compound</u>	R^1	<u>Base</u>
	<u>VII</u> 1	$(CH_3)_3C$	Guanine
	<u>VII</u> 2	$(CH_3)_3C$	Adenine
30	<u>VII</u> 3	$(CH_3)_3C$	Thymine
	<u>VII</u> 4	$(CH_3)_3C$	Uracil
	<u>VII</u> 5	$(CH_3)_3C$	Cytosine
	<u>VII</u> 6	$(CH_3)_3C$	Xanthine

35 These compounds were prepared from the parent free acyclic nucleotides by condensation with bis(acyloxymethyl) phosphate or mono(acyloxymethyl) phosphate as described above for the uracil (II),

cytosine (IV), and purine (V) analogues.

* * *

5 Testing of these compounds has confirmed that the protective groups are removed under the appropriate conditions. Some of the compounds have been tested for biological activity, and have shown positive results.


10 Methods in accordance with the present invention comprise administering to a mammal an effective amount of one or more of the compounds described above. The administering step is preferably by intravenous, intraarterial, intramuscular, intralymphatic,
15 intraperitoneal, subcutaneous, intrapleural or intrathecal injection or by topical application or oral dosage.

* * *

20 The preceding examples and description are intended to be illustrative, but not to limit the scope of the invention. Those skilled in the art will appreciate that the present invention has a number of potential
25 applications and a variety of possible embodiments.

CLAIMS:

1. Compounds having the formula



where R^1 is selected from the group consisting of H, alkyl hydrocarbons having 1-10 carbons, aryl and alkaryl hydrocarbons having 6-10 carbons, and amines having the formula NR^4R^5 , where R^4 and R^5 are independently selected from the group consisting of H and alkyl hydrocarbons having 1-10 carbons;

R^3 is selected from the group consisting of H and alkyl hydrocarbons having 1-3 carbons;

X^1 is selected from the group consisting of H and $\text{R}^1\text{COOCR}_2^3$

X^2 is selected from the group consisting of H and R^2OR^2 ; and

R^2 is selected from the group consisting of H, alkyl hydrocarbons having 1-10 carbons, aryl and alkaryl hydrocarbons having 6-10 carbons, and nucleosides.

2. The compounds of claim 1, where R^1 is selected from the group consisting of H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$.

3. The compounds of claim 1, where R^3 is H.


4. The compounds of claim 1, where R^2 is selected from the group consisting of

uracil 2',3'-dideoxynucleosides,
cytosine 2',3'-dideoxynucleosides,
purine 2',3'-dideoxynucleosides, and
pyrimidine acyclic nucleosides.

5. The compounds of claim 1, where R^2 is selected from the group consisting of

2',3'-dideoxyuridin-5'-yl groups
2',3'-dideoxycytidin-5'-yl groups
2',3'-dideoxyguanosin-5'-yl groups,

and groups having the formula



where B is a base selected from the group consisting of thymine, uracil, cytosine, guanine, adenine, and xanthine.

6. The compounds of claim 1, where R^2 is selected from the group consisting of


2',3'-dideoxyuridine-5'-yl
2'-fluoro-2',3'-dideoxyuridine-5'-yl
3'-fluoro-2',3'-dideoxyuridine-5'-yl
3'-azido-2',3'-dideoxyuridine-5'-yl
3'-amino-2',3'-dideoxyuridine-5'-yl
5-chloro-2',3'-dideoxyuridine-5'-yl
5-bromo-2',3'-dideoxyuridine-5'-yl
5-iodo-2',3'-dideoxyuridine-5'-yl
5-methyl-2',3'-dideoxyuridine-5'-yl
5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-yl
5-methyl-3'-azido-2',3'-dideoxyuridine-5'-yl

- 5-methyl-3'-amino-2',3'-dideoxyuridine-5'-yl
 5-ethyl-2',3'-dideoxyuridine-5'-yl
 5-propyl-2',3'-dideoxyuridine-5'-yl
 2',3'-dideoxycytidin-5'-yl
 5 2'-fluoro-2',3'-dideoxycytidin-5'-yl
 3'-fluoro-2',3'-dideoxycytidin-5'-yl
 3'-azido-2',3'-dideoxycytidin-5'-yl
 5-fluoro-2',3'-dideoxycytidin-5'-yl
 5-chloro-2',3'-dideoxycytidin-5'-yl
 10 5-bromo-2',3'-dideoxycytidin-5'-yl
 5-iodo-2',3'-dideoxycytidin-5'-yl
 5-methyl-2',3'-dideoxycytidin-5'-yl
 5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl
 5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl
 15 2',3'-dideoxyadenosin-5'-yl
 2',3'-dideoxyguanosin-5'-yl
 2',3'-dideoxyxanthosin-5'-yl
 CH₂CH₂OCH₂ Guanine
 CH₂CH₂OCH₂ Adenine
 20 CH₂CH₂OCH₂ Thymine
 CH₂CH₂OCH₂ Uracil
 CH₂CH₂OCH₂ Cytosine
 CH₂CH₂OCH₂ Xanthine

25

7. Compounds having the formula

30



where R¹ is selected from the group consisting of
 35 CH₃, CH₂CH₃, CH(CH₃)₂, and C(CH₃)₃;

X¹ is selected from the group consisting of H and
 R¹COOCH₂; and

R^2 is selected from the group consisting of

2',3'-dideoxyuridin-5'-yl groups

2',3'-dideoxycytidin-5'-yl groups

5 2',3'-dideoxyguanosin-5'-yl groups,


and groups having the formula



where B is a base selected from the group consisting of
thymine, uracil, cytosine, guanine, adenine, and
10 xanthine.

8. Compounds having the formula

15



where R^1 is selected from the group consisting of H, CH_3 ,
 CH_2CH_3 , $CH(CH_3)_2$, and $C(CH_3)_3$; and

25

R^2 is selected from the group consisting of

2',3'-dideoxyuridine-5'-yl

2'-fluoro-2',3'-dideoxyuridine-5'-yl

30 3'-fluoro-2',3'-dideoxyuridine-5'-yl

3'-azido-2',3'-dideoxyuridine-5'-yl

3'-amino-2',3'-dideoxyuridine-5'-yl

5-chloro-2',3'-dideoxyuridine-5'-yl

5-bromo-2',3'-dideoxyuridine-5'-yl

35 5-iodo-2',3'-dideoxyuridine-5'-yl

5-methyl-2',3'-dideoxyuridine-5'-yl

5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-yl

5-methyl-3'-azido-2',3'-dideoxyuridine-5'-yl

35

- 5-methyl-3'-amino-2',3'-dideoxyuridine-5'-yl
 5-ethyl-2',3'-dideoxyuridine-5'-yl
 5-propyl-2',3'-dideoxyuridine-5'-yl
 2',3'-dideoxycytidin-5'-yl
 5 2'-fluoro-2',3'-dideoxycytidin-5'-yl
 3'-fluoro-2',3'-dideoxycytidin-5'-yl
 3'-azido-2',3'-dideoxycytidin-5'-yl
 5-fluoro-2',3'-dideoxycytidin-5'-yl
 5-chloro-2',3'-dideoxycytidin-5'-yl
 10 5-bromo-2',3'-dideoxycytidin-5'-yl
 5-iodo-2',3'-dideoxycytidin-5'-yl
 5-methyl-2',3'-dideoxycytidin-5'-yl
 5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl
 5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl
 15 2',3'-dideoxyadenosin-5'-yl
 2',3'-dideoxyguanosin-5'-yl
 2',3'-dideoxyxanthosin-5'-yl
 CH₂CH₂OCH₂ Guanine
 CH₂CH₂OCH₂ Adenine
 20 CH₂CH₂OCH₂ Thymine
 CH₂CH₂OCH₂ Uracil
 CH₂CH₂OCH₂ Cytosine
 CH₂CH₂OCH₂ Xanthine

25

9. Compounds having the formula



35

where R¹ is selected from the group consisting of H, CH₃, CH₂CH₃, CH(CH₃)₂, and C(CH₃)₃; and

R² is selected from the group consisting of


2',3'-dideoxyuridine-5'-yl

- 2'-fluoro-2',3'-dideoxyuridine-5'-yl
 3'-fluoro-2',3'-dideoxyuridine-5'-yl
 3'-azido-2',3'-dideoxyuridine-5'-yl
 3'-amino-2',3'-dideoxyuridine-5'-yl
 5 5-chloro-2',3'-dideoxyuridine-5'-yl
 5-bromo-2',3'-dideoxyuridine-5'-yl
 5-iodo-2',3'-dideoxyuridine-5'-yl
 5-methyl-2',3'-dideoxyuridine-5'-yl
 5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-yl
 10 5-methyl-3'-azido-2',3'-dideoxyuridine-5'-yl
 5-methyl-3'-amino-2',3'-dideoxyuridine-5'-yl
 5-ethyl-2',3'-dideoxyuridine-5'-yl
 5-propyl-2',3'-dideoxyuridine-5'-yl
 2',3'-dideoxycytidin-5'-yl
 15 2'-fluoro-2',3'-dideoxycytidin-5'-yl
 3'-fluoro-2',3'-dideoxycytidin-5'-yl
 3'-azido-2',3'-dideoxycytidin-5'-yl
 5-fluoro-2',3'-dideoxycytidin-5'-yl
 5-chloro-2',3'-dideoxycytidin-5'-yl
 20 5-bromo-2',3'-dideoxycytidin-5'-yl
 5-iodo-2',3'-dideoxycytidin-5'-yl
 5-methyl-2',3'-dideoxycytidin-5'-yl
 5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl
 5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl
 25 2',3'-dideoxyadenosin-5'-yl
 2',3'-dideoxyguanosin-5'-yl
 2',3'-dideoxyxanthosin-5'-yl
 CH₂CH₂OCH₂ Guanine
 CH₂CH₂OCH₂ Adenine
 30 CH₂CH₂OCH₂ Thymine
 CH₂CH₂OCH₂ Uracil
 CH₂CH₂OCH₂ Cytosine
 CH₂CH₂OCH₂ Xanthine

35

10. Compounds having the formula

37



where R^1 is selected from the group consisting of H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$; and

R^2 is selected from the group consisting of


- 15
- 2',3'-dideoxyuridine-5'-yl
 - 2'-fluoro-2',3'-dideoxyuridine-5'-yl
 - 3'-fluoro-2',3'-dideoxyuridine-5'-yl
 - 3'-azido-2',3'-dideoxyuridine-5'-yl
 - 3'-amino-2',3'-dideoxyuridine-5'-yl
 - 5-chloro-2',3'-dideoxyuridine-5'-yl
 - 20 5-bromo-2',3'-dideoxyuridine-5'-yl
 - 5-iodo-2',3'-dideoxyuridine-5'-yl
 - 5-methyl-2',3'-dideoxyuridine-5'-yl
 - 5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-yl
 - 5-methyl-3'-azido-2',3'-dideoxyuridine-5'-yl
 - 25 5-methyl-3'-amino-2',3'-dideoxyuridine-5'-yl
 - 5-ethyl-2',3'-dideoxyuridine-5'-yl
 - 5-propyl-2',3'-dideoxyuridine-5'-yl
 - 2',3'-dideoxycytidin-5'-yl
 - 2'-fluoro-2',3'-dideoxycytidin-5'-yl
 - 30 3'-fluoro-2',3'-dideoxycytidin-5'-yl
 - 3'-azido-2',3'-dideoxycytidin-5'-yl
 - 5-fluoro-2',3'-dideoxycytidin-5'-yl
 - 5-chloro-2',3'-dideoxycytidin-5'-yl
 - 5-bromo-2',3'-dideoxycytidin-5'-yl
 - 35 5-iodo-2',3'-dideoxycytidin-5'-yl
 - 5-methyl-2',3'-dideoxycytidin-5'-yl
 - 5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl

5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl

11. Compounds having the formula

5

10



where R^1 is selected from the group consisting of H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$; and

15 R^2 is selected from the group consisting of

- 20
- 2',3'-dideoxyuridine-5'-yl
 - 2'-fluoro-2',3'-dideoxyuridine-5'-yl
 - 3'-fluoro-2',3'-dideoxyuridine-5'-yl
 - 3'-azido-2',3'-dideoxyuridine-5'-yl
 - 3'-amino-2',3'-dideoxyuridine-5'-yl
 - 5-chloro-2',3'-dideoxyuridine-5'-yl
 - 5-bromo-2',3'-dideoxyuridine-5'-yl
 - 5-iodo-2',3'-dideoxyuridine-5'-yl
 - 25 5-methyl-2',3'-dideoxyuridine-5'-yl
 - 5-methyl-3'-fluoro-2',3'-dideoxyuridine-5'-yl
 - 5-methyl-3'-azido-2',3'-dideoxyuridine-5'-yl
 - 5-methyl-3'-amino-2',3'-dideoxyuridine-5'-yl
 - 5-ethyl-2',3'-dideoxyuridine-5'-yl
 - 30 5-propyl-2',3'-dideoxyuridine-5'-yl
 - 2',3'-dideoxycytidin-5'-yl
 - 2'-fluoro-2',3'-dideoxycytidin-5'-yl
 - 3'-fluoro-2',3'-dideoxycytidin-5'-yl
 - 3'-azido-2',3'-dideoxycytidin-5'-yl
 - 35 5-fluoro-2',3'-dideoxycytidin-5'-yl
 - 5-chloro-2',3'-dideoxycytidin-5'-yl
 - 5-bromo-2',3'-dideoxycytidin-5'-yl

39

5-iodo-2',3'-dideoxycytidin-5'-yl

5-methyl-2',3'-dideoxycytidin-5'-yl


5-methyl-3'-fluoro-2',3'-dideoxycytidin-5'-yl

5-methyl-3'-azido-2',3'-dideoxycytidin-5'-yl

5

12. Compounds having the formula


40



10 where R^1 is selected from the group consisting of H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$; and

15 R^2 is selected from the group consisting of
 $2',3'$ -dideoxyadensosin-5'-yl,
 $2',3'$ -dideoxyguanosin-5'-yl, and
 $2',3'$ -dideoxyxanthosin-5'-yl.

20 13. Compounds having the formula




30 where R^1 is selected from the group consisting of H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$; and

35 B is a base selected from the group consisting of
guanine, adenine, thymine, uracil, cytosine, and
xanthine.

14. Compounds having the formula

41



10 where R^1 is selected from the group consisting of H, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, and $\text{C}(\text{CH}_3)_3$; and

15 B is a base selected from the group consisting of guanine, adenine, thymine, uracil, cytosine, and xanthine.

15

15. A method of providing phosphates intracellularly, comprising:


20

administering to a mammal an effective amount of a compound in accordance with claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.

AMENDED CLAIMS

[received by the International Bureau
on 2 July 1990 (02.07.90);
original claims 7-14 cancelled; original claims 1 and 15 amended;
other claims unchanged (2 pages)]

1. Compounds having the formula



where R^1 is selected from the group consisting of H, alkyl hydrocarbons having 1-10 carbons, aryl and alkaryl hydrocarbons having 6-10 carbons, and amines having the formula NR^4R^5 , where R^4 and R^5 are independently selected from the group consisting of H and alkyl hydrocarbons having 1-10 carbons;

R^3 is selected from the group consisting of H and alkyl hydrocarbons having 1-3 carbons;

X^1 is selected from the group consisting of H and $\text{R}^1\text{COOCR}_2^3$

X^2 is selected from the group consisting of H and R^2 ; and

R^2 is selected from the group consisting of H, alkyl hydrocarbons having 1-10 carbons, aryl and alkaryl hydrocarbons having 6-10 carbons, and nucleosides.

- 43 -



15. A method of providing phosphates intracellularly,
comprising:

5 administering to a mammal an effective amount of a
compound in accordance with claim 1, 2, 3, 4, 5,
or 6.

- 44 -

STATEMENT UNDER ARTICLE 19

Applicant has amended the claims in this application to cover only phosphonate compounds; i.e. where X^2 is selected from the group consisting of R^2 . All of the references cited in the International Search Report as destroying novelty or the presence of an inventive step for the present invention are believed to disclose only phosphate compounds. Therefore, the concurrently submitted amendment limits the claims in a way that distinguishes them from that which is taught by the references.



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 89/05766

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 H 19/10, 19/20, C 07 F 9/09, 9/40														
II. FIELDS SEARCHED <div style="text-align: right; margin-right: 50px;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC5</td> <td style="padding: 5px;">C 07 H; C 07 F</td> </tr> </table> <div style="text-align: center; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div>			Classification System	Classification Symbols	IPC5	C 07 H; C 07 F								
Classification System	Classification Symbols													
IPC5	C 07 H; C 07 F													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category *</th> <th style="width: 60%; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 72, No. 3, March 1983, D. Farquhar et al.: "Biologically reversible phosphate-protective groups", see page 324 - page 325 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-14</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">International Cancer Congress, Proceedings, 13th International Cancer Congress, Abstract 1789, Vol. 13(1982), David Farquhar et al.: "5-fluoro-2'-deoxyuridine-5'-phosphate (5-FdUMP), bis(acyloxy-methyl) esters: potential prodrugs of 5-FdUMP. see the whole article --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-14</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Bioorg. Chem., Vol. 12, No. 2, 1984, Srivastva Devendra N. et al.: "Bioreversible phosphate protective groups: synthesis and stability of model acyloxomethyl phosphates", see page 118 - page 129 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-14</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 72, No. 3, March 1983, D. Farquhar et al.: "Biologically reversible phosphate-protective groups", see page 324 - page 325 --	1-14	X	International Cancer Congress, Proceedings, 13th International Cancer Congress, Abstract 1789, Vol. 13(1982), David Farquhar et al.: "5-fluoro-2'-deoxyuridine-5'-phosphate (5-FdUMP), bis(acyloxy-methyl) esters: potential prodrugs of 5-FdUMP. see the whole article --	1-14	X	Bioorg. Chem., Vol. 12, No. 2, 1984, Srivastva Devendra N. et al.: "Bioreversible phosphate protective groups: synthesis and stability of model acyloxomethyl phosphates", see page 118 - page 129 --	1-14
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 72, No. 3, March 1983, D. Farquhar et al.: "Biologically reversible phosphate-protective groups", see page 324 - page 325 --	1-14												
X	International Cancer Congress, Proceedings, 13th International Cancer Congress, Abstract 1789, Vol. 13(1982), David Farquhar et al.: "5-fluoro-2'-deoxyuridine-5'-phosphate (5-FdUMP), bis(acyloxy-methyl) esters: potential prodrugs of 5-FdUMP. see the whole article --	1-14												
X	Bioorg. Chem., Vol. 12, No. 2, 1984, Srivastva Devendra N. et al.: "Bioreversible phosphate protective groups: synthesis and stability of model acyloxomethyl phosphates", see page 118 - page 129 --	1-14												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search 26th April 1990 </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report 14 MAY 1990 </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority EUROPEAN PATENT OFFICE </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer MISS P. S. KOWALCZYK </td> </tr> </table>			Date of the Actual Completion of the International Search 26th April 1990	Date of Mailing of this International Search Report 14 MAY 1990	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer MISS P. S. KOWALCZYK								
Date of the Actual Completion of the International Search 26th April 1990	Date of Mailing of this International Search Report 14 MAY 1990													
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer MISS P. S. KOWALCZYK													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P,X	US, A, 4816570 (DAVID FARQUHAR) 28 March 1989, see the whole document --	1-14
P,X	Biochemical Pharmacology, Vol. 38, No. 19, 1989, Jerome J. Freed et al.: "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxy- ribonucleotides as extracellular sources of active 5'-deoxy-ribonucleotides in cultured cells ", see page 3193 - page 3198 ---	1-14
X	Chemical Abstracts, vol. 101, no. 17, 22 October 1984, (Columbus, Ohio, US), Ghyczy Miklos et al.: "Pesticides", see page 255, abstract 146138b, & Ger. Offen. DE 3,248,033 --	1
A	J. Med. Chem., Vol. 27, 1984, Roger N. Hunstone et al.: "Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine ", see page 440 - page 444 --	1-14
A	US, A, 3284440 (ARTHUR A. PATCHETT ET AL.) 8 November 1966, see particularly claims, column 1 lines 53-59 -- -----	1-14

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 15 because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1 (iv) :

Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 89/05766

SA 33993

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 30/03/90
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4816570	28/03/89	NONE	
US-A- 3284440	08/11/66	CH-A- 487182	15/03/70
		DE-A- 1595938	09/07/70
		FR-M- 4812	00/00/00
		FR-A- 1589360	31/03/70
		GB-A- 1090466	00/00/00
		NL-A- 6507496	13/12/65

For more details about this annex: see Official Journal of the European patent Office, No. 12/82